Form 4: ALX Oncology SVP, Finance and CAO, Shelly Pinto, Acquires 3,000 Shares Following Achievement of Performance Metrics

Shelly Pinto, SVP, Finance and CAO of ALX Oncology Holdings Inc., acquired 3,000 shares of common stock on March 14, 2025, following the achievement of performance metrics related to the ASPEN-06 clinical trials.

Summary

• On March 14, 2025, Shelly Pinto, the SVP, Finance and CAO of ALX Oncology Holdings Inc., acquired 3,000 shares of common stock.
• The acquisition was a result of achieving certain performance metrics related to the positive results of the ASPEN-06 clinical trials.
• These shares are represented by performance share units (PSUs) and vest on March 14, 2026.
• Following the transaction, Pinto directly owns 90,352 shares of ALX Oncology Holdings Inc.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive due to the achievement of performance metrics and the subsequent acquisition of shares by a company executive, indicating confidence in the company's prospects. However, it's a routine filing, so the impact is limited.

Positives

• The acquisition of shares by a high-ranking officer signals confidence in the company's performance and future prospects.
• The achievement of performance metrics related to the ASPEN-06 clinical trials suggests positive developments in the company's clinical programs.

Future Outlook

The document does not contain explicit forward-looking statements, but the vesting of the PSUs on March 14, 2026, suggests a continued commitment to the company's long-term performance.

Management Comments

• The reported shares are represented by performance share units, or PSUs, and were awarded upon the achievement of certain performance metrics related to the positive results for ASPEN-06 clinical trials.

Industry Context

This Form 4 filing indicates insider activity related to performance achievements, which is common in the biotechnology industry where clinical trial results significantly impact company value. Positive results from ASPEN-06 likely contributed to the awarding of these shares.

Comparison to Industry Standards

• In the biotechnology industry, stock options and performance share units are frequently used to incentivize executives and align their interests with those of shareholders.
• Companies like Amgen, Gilead Sciences, and Regeneron Pharmaceuticals also utilize similar compensation structures based on clinical trial milestones and overall company performance.
• The vesting period of the PSUs (March 14, 2026) is a typical timeframe for such awards, allowing for sustained performance evaluation.

Stakeholder Impact

• Shareholders may view the acquisition of shares by a company executive as a positive signal.
• Employees may be motivated by the company's achievement of performance metrics.

Key Dates